<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001015" GROUP_ID="DEMENTIA" ID="226399092414425717" MERGED_FROM="" MODIFIED="2008-11-04 15:48:47 +0100" MODIFIED_BY="Helen Collins" REVIEW_NO="19" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2008-11-04 15:48:47 +0100" MODIFIED_BY="Helen Collins">
<TITLE>Lecithin for dementia and cognitive impairment</TITLE>
<CONTACT MODIFIED="2008-11-04 15:48:47 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="7628" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julian</FIRST_NAME><MIDDLE_INITIALS>PT</MIDDLE_INITIALS><LAST_NAME>Higgins</LAST_NAME><POSITION>Senior Statistician</POSITION><EMAIL_1>julian.higgins@mrc-bsu.cam.ac.uk</EMAIL_1><URL>www.mrc-bsu.cam.ac.uk</URL><ADDRESS><ORGANISATION>MRC Biostatistics Unit</ORGANISATION><ADDRESS_1>Institute of Public Health</ADDRESS_1><ADDRESS_2>Robinson Way</ADDRESS_2><CITY>Cambridge</CITY><ZIP>CB2 0SR</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1223 330396</PHONE_1><PHONE_2>+44 1223 330366</PHONE_2><FAX_1>+44 1223 330388</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-04 15:48:47 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="7628" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julian</FIRST_NAME><MIDDLE_INITIALS>PT</MIDDLE_INITIALS><LAST_NAME>Higgins</LAST_NAME><POSITION>Senior Statistician</POSITION><EMAIL_1>julian.higgins@mrc-bsu.cam.ac.uk</EMAIL_1><URL>www.mrc-bsu.cam.ac.uk</URL><ADDRESS><ORGANISATION>MRC Biostatistics Unit</ORGANISATION><ADDRESS_1>Institute of Public Health</ADDRESS_1><ADDRESS_2>Robinson Way</ADDRESS_2><CITY>Cambridge</CITY><ZIP>CB2 0SR</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1223 330396</PHONE_1><PHONE_2>+44 1223 330366</PHONE_2><FAX_1>+44 1223 330388</FAX_1></ADDRESS></PERSON><PERSON ID="4621" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Leon</FIRST_NAME><LAST_NAME>Flicker</LAST_NAME><POSITION>Professor of Geriatric Medicine</POSITION><EMAIL_1>leonflic@cyllene.uwa.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Western Australian Centre for Health &amp; Ageing - WACHA</DEPARTMENT><ORGANISATION>University of Western Australia</ORGANISATION><ADDRESS_1>Royal Perth Hospital</ADDRESS_1><ADDRESS_2>Box X2213</ADDRESS_2><CITY>Perth</CITY><ZIP>6847</ZIP><REGION>Western Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>618 9224 3992</PHONE_1><PHONE_2>618 9224 2750</PHONE_2><FAX_1>618 9224 2063</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-04 14:38:46 +0000" MODIFIED_BY="Helen Collins">
<UP_TO_DATE>
<DATE DAY="6" MONTH="5" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="5" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="27" MONTH="3" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-04 14:36:35 +0000" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="4" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-04 14:36:35 +0000" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-04 14:36:35 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="6" MONTH="5" YEAR="2004"/>
<DESCRIPTION>
<P>August 2004: An update search was carried out on 6 May 2004 and some additional references to an already included trial (Crapper McLachlan) were found. There were no new data and the conclusions of the review have not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="28" MONTH="8" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Institute of Child Health, London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Imperial College School of Medicine, London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The University of Reading</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-04 14:36:50 +0000" MODIFIED_BY="Helen Collins">
<SUMMARY MODIFIED="2008-11-04 14:36:50 +0000" MODIFIED_BY="Helen Collins">
<TITLE MODIFIED="2008-11-04 14:36:50 +0000" MODIFIED_BY="Helen Collins">Doubtful effect of lecithin as a treatment for dementia</TITLE>
<SUMMARY_BODY>
<P>Lecithin is a major dietary source of choline, a substance that may theoretically improve brain functioning in people with dementia or similar problems (including Alzheimer's disease). This review did not find any evidence that lecithin does have a benefit for patients with Alzheimer's disease or other forms of dementia. However, one small study has observed a dramatic benefit of lecithin in people with subjective memory problems, but there are no similar studies with which to compare it.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Alzheimer's disease sufferers have been found to lack the enzyme responsible for converting choline into acetylcholine within the brain. Lecithin is a major dietary source of choline, so extra consumption may reduce the progression of dementia.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy of lecithin in the treatment of dementia or cognitive impairment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched on 6 May 2004 using the terms lecithin and phosphatidylcholine. This register contains records from all major databases and many trials databases and is updated regularly. Reference lists and relevant books have been examined.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All unconfounded, randomized trials comparing lecithin with placebo in a treatment period longer than one day, in patients with dementia of the Alzheimer type, vascular dementia, mixed vascular and Alzheimer's disease, unclassified or other dementia or unclassified cognitive impairment not fulfilling the criteria for dementia are eligible for inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted independently by two reviewers and cross-checked. Meta-analyses were performed when more than one trial provided data on a comparable outcome on sufficiently similar patients. Random effects analyses were performed whenever heterogeneity between results appeared to be present. Standardised differences in mean outcome measures were used due to the use of different scales and periods of treatment. Odds ratios for dichotomous data were pooled using the Mantel-Haenszel or DerSimonian and Laird methods.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twelve randomized trials have been identified involving patients with Alzheimer's disease (265 patients), Parkinsonian dementia (21 patients) and subjective memory problems (90 patients). No trials reported any clear clinical benefit of lecithin for Alzheimer's disease or Parkinsonian dementia. Few trials contributed data to meta-analyses. The only statistically significant result was in favour of placebo for adverse events, based on one trial, which appears likely to be a spurious result. A dramatic result in favour of lecithin was obtained in a trial of subjects with subjective memory problems.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Evidence from randomized trials does not support the use of lecithin in the treatment of patients with dementia. A moderate effect cannot be ruled out, but results from the small trials to date do not indicate priority for a large randomized trial. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>There is a great deal of evidence that cholinergic pathways are important for normal memory and the pathogenesis of the memory impairment in dementia, and in particular that their loss contributes to Alzheimer's disease. Postmortem studies of the brains of patients with Alzheimer's disease have demonstrated a marked reduction in the number of neurons in the cholinergic nuclei and a reduced amount of the enzyme choline acetyltransferase which is responsible for the formation of acetylcholine from choline. </P>
<P>Lecithin is a choline-containing phospholipid and is the major dietary source of choline. It has been shown to increase serum choline levels more effectively than orally administered choline (<LINK REF="REF-Wurtman-1977" TYPE="REFERENCE">Wurtman 1977</LINK>). It has been postulated that lecithin may accelerate acetylcholine synthesis in the brain through enhanced availability of the substrate choline. It has been tried alone or in combination with an acetylcholinesterase inhibitor in the treatment of dementia. It is readily available from non-pharmaceutical sources including health food outlets.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the clinical efficacy of lecithin in the treatment of dementia or cognitive impairment.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Included in the review are all relevant unconfounded, randomized controlled trials, published or unpublished, in which treatment allocation was concealed and assessment of outcomes was blind. The period of treatment must exceed one day. Published studies are included irrespective of the language in which they were published. The first treatment period of crossover studies is included, since most conditions under evaluation are degenerative. Only results from post-randomization periods of the studies are used.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Trials involving the following types of participants are eligible for the review:<BR/>1. Patients diagnosed using operational criteria with these types of dementia:<BR/>
</P>
<UL>
<LI>Alzheimer's disease</LI>
<LI>vascular dementia</LI>
<LI>mixed Alzheimer's disease and vascular dementia</LI>
<LI>unclassified or other dementia</LI>
</UL>
<P>
<BR/>2. Patients with cognitive impairment not fulfilling accepted criteria for the classification of dementia. Subjects with subjective symptoms of cognitive disturbance are also included.</P>
<P>Diagnosis of dementia may be made by a number of operational criteria including DSM-IV (Diagnostic and Statistical Manual of Mental Disorders <LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>)), ICD (International [Statistical] Classification of Diseases, <LINK REF="REF-Bramer-1988" TYPE="REFERENCE">Bramer 1988</LINK>), NINCDS-ADRDA (National Institute of Neurological, Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association, <LINK REF="REF-McKhann-1984" TYPE="REFERENCE">McKhann 1984</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Studies in which lecithin (phosphatidylcholine), at any dose, was compared with a placebo control for a period of more than one day are considered for inclusion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcomes of interest are:<BR/>
</P>
<UL>
<LI>dependency (such as institutionalisation)</LI>
<LI>global impression</LI>
<LI>functional performance</LI>
<LI>behavioural disturbance</LI>
<LI>quality of life</LI>
<LI>cognitive function (as measured by psychometric tests)</LI>
<LI>effect on care</LI>
<LI>death</LI>
<LI>acceptability of treatment as measured by withdrawal from trial</LI>
<LI>safety as measured by the incidence of adverse effects (including side-effects) leading to withdrawal</LI>
</UL>
<P>
<BR/>Studies which report only physiological outcomes such as plasma levels, changes on functional imaging or EEG changes will be included but will not contribute to analyses.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>1. The Cochrane Dementia and Cognitive Improvement Group's Specialized Register of Clinical Trials was searched on 6 May 2004 using the terms lecithin and phosphatidylcholine to identify new trials. At that time the Register contained records from the following databases:</P>
<P>CENTRAL: <I>The Cochrane Library</I> Issue 2, 2004;<BR/>MEDLINE (January 1966 to February 2004);<BR/>EMBASE (January 1980 to February 2004);<BR/>PsycINFO (January 1887 to January 2004);<BR/>CINAHL (January 1982 to January 2004);<BR/>SIGLE: Grey Literature in Europe (January 1980 to December 2002);<BR/>ISTP: Index to Scientific and Technical Proceedings (to May 2000);<BR/>INSIDE: British Library database of Conference Proceedings and Journals (to June 2000);<BR/>Aslib Index to Theses (UK and Ireland theses) (January 1970 to March 2003);<BR/>Dissertation Abstract (USA) (January 1861 to March 2003);<BR/>ADEAR: Alzheimer's Disease Clinical Trials Database (to March 2004); <BR/>National Research Register Issue 1, 2004;<BR/>Current Controlled trials (last searched March 2004) which includes:<BR/> Alzheimer Society<BR/> GlaxoSmithKline<BR/> Hong Kong Health Services Research Fund<BR/> Medical Research Council (MRC)<BR/> NHS R&amp;D Health Technology Assessment Programme<BR/> Schering Health Care Ltd<BR/> South Australian Network for Research on Ageing<BR/> US Dept of Veterans Affairs Cooperative Studies<BR/> National Institutes of Health (NIH)<BR/>ClinicalTrials.gov (last searched March 2004);<BR/>LILACS: Latin American and Caribbean Health Science Literature (last searched April 2003).<BR/>
<BR/>The search strategies used to identify relevant records in MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS can be found in the Group's module.</P>
<P>2. Companies responsible for marketing lecithin werecontacted and requested to provide information on additional randomized trials.<BR/>3. Reference lists of retrieved articles (especially literature reviews) were examined for additional trials.<BR/>4. Books concerning lecithin or treatment of Alzheimer's disease were hand searched for additional trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>SELECTION OF TRIALS</B>
<BR/>Titles and abstracts of citations obtained from the search were examined by both reviewers and any obviously irrelevant articles discarded. If an article appeared to describe a randomized controlled trial, it was retrieved for further assessment.<BR/>
<BR/>Both reviewers independently assessed retrieved articles for inclusion in the review according to the criteria above. Disagreements were resolved by discussion. Any persisting differences were to be adjudicated by an editor of the Cochrane Dementia and Cognitive Impairment Group, though this was not required.</P>
<P>
<B>ASSESSMENT OF METHODOLOGY AND QUALITY</B>
<BR/>The trial conduct and methodological quality were assessed by both reviewers. Randomization and (probable) blind assessment of outcome were threshold criteria for inclusion in the review. In addition, whether participants were blind to their treatment allocation and whether drop-out was judged to be severe (and a potential source of bias) were collected for use in sensitivity analyses.</P>
<P>For presentation in <I>The Cochrane Library</I>, concealment of allocation to treatment was rated according to the following three categories:</P>
<P>
<U>Category A (adequate)</U>
<BR/>The report describes allocation of treatment by: <BR/>(i) some form of centralised randomized scheme, such as having to provide details of an enrolled participant to an office by phone to receive the treatment group allocation; <BR/>(ii) some form of randomization scheme controlled by a pharmacy; <BR/>(iii) numbered or coded containers, such as in a pharmaceutical trial in which capsules from identical-looking numbered bottles are administrated sequentially to enrolled participants; <BR/>(iv) an on-site or coded computer system, given that the allocations were in a locked, unreadable file that could be accessed only after inputting the characteristics of an enrolled participant;<BR/>(v) assignment envelopes with the specification that they were at least sequentially numbered, sealed, opaque envelopes; <BR/>(vi) other combinations of described elements of the process which provide assurance of adequate concealment.</P>
<P>
<U>Category B (intermediate)</U>
<BR/>The report describes allocation of treatment by: <BR/>(i) use of a 'list' or 'table' to allocate assignment; <BR/>(ii) use of 'envelopes' or 'sealed envelopes'; <BR/>(iii) stating the study as 'randomized' without further detail.</P>
<P>
<U>Category C (inadequate)</U>
<BR/>The report describes allocation of treatment by: <BR/>(i) alternation; <BR/>(ii) reference to case record numbers, dates of birth, day of week, or any other such approach; <BR/>(iii) any allocation procedure that is entirely transparent before assignment, such as an open list of random numbers or assignments.</P>
<P>Empirical research has demonstrated that lack of adequate allocation concealment is associated with bias. Trials which have taken inadequate measures to conceal allocation have been shown to yield more pronounced estimates of treatment effect than trials which have taken adequate measures. Trials with unclear allocation concealment produce estimates less pronounced than inadequately concealed trials, but more pronounced than adequately concealed trials (<LINK REF="REF-Kunz-2002" TYPE="REFERENCE">Kunz 2002</LINK>). </P>
<P>Trials are included if they conform to categories A or B; those falling into category C are excluded.</P>
<P>
<B>DATA EXTRACTION<BR/>
</B>The reviewers extracted data independently from included papers. Data were cross-checked and any discrepancies discussed.</P>
<P>To enable an intention-to-treat analysis, data were sought for every patient, irrespective of compliance, whether or not the patient was subsequently deemed ineligible or otherwise excluded from the treatment or follow-up. Where dichotomous data were missing, patients were assumed to have suffered the less favourable outcome. If continuous data were missing, 'on-treatment' results were extracted and indicated as such.</P>
<P>For continuous and ordinal variables, both change from baseline and final value were extracted when available. The baseline score was taken to be the latest score on or before the date of randomization not falling earlier than two months before randomization. No results concerning the efficacy or safety of the treatment were extracted from pre-randomization periods.</P>
<P>Results from the first treatment period only of crossover studies were extracted. </P>
<P>
<B>DATA ANALYSIS</B>
<BR/>Meta-analysis was performed only on sets of studies which were considered to address sufficiently similar populations and outcomes. </P>
<P>Dichotomous outcomes such as global impression (of improvement) and death were pooled using the method of Mantel and Haenszel.<BR/>
<BR/>For continuous variables, change from baseline was analysed in preference to final values. Where studies addressed the same scale of measurement, a difference in means was used to assess treatment effect; where a variety of scales were used to measure the same clinical outcome, a standardized mean difference was used.</P>
<P>Ordinal variables such as psychometric scores, and clinical global impression, functional and quality of life scales were likely to be commonplace. If sufficiently detailed data were available, these were to be analysed using methods explicit to ordinal data (<LINK REF="REF-Whitehead-1994" TYPE="REFERENCE">Whitehead 1994</LINK>). However, the required data were not available, so such outcomes were treated as continuous data. No obvious deviations from normality were identified.</P>
<P>A test for heterogeneity was undertaken prior to each meta-analysis, and if homogeneity of treatment effects was not indicated a random effects analysis was performed.</P>
<P>Depending on sufficient data, additional hypotheses were to be examined, using subgroup analyses, as follows:<BR/>1. Breakdown by disease: <BR/> - Alzheimer's disease<BR/> - vascular dementia<BR/> - mixed Alzheimer's disease and vascular dementia<BR/> - unclassified or other dementia<BR/> - cognitive impairment<BR/>2. Duration of treatment<BR/> - &lt; 12 weeks<BR/> - &gt;= 12 weeks<BR/>3. Severity of dementia at baseline<BR/> - mild (MMSE &gt; 17 or similar)<BR/> - moderate (MMSE 10-17 or similar)<BR/> - severe (MMSE &lt; 10 or similar)</P>
<P>Sensitivity analyses were to be performed using the following subgroup analyses:<BR/>1. Blinding<BR/> - double-blind<BR/> - single-blind<BR/>2. Drop-out<BR/> - unlikely to cause bias<BR/> - potentially leading to bias</P>
<P>The following sensitivity analyses were also be performed by re-analysis of the data:<BR/>1. Imputation of missing dichotomous data<BR/> - assuming missing outcomes were less favourable<BR/> - analysis as presented</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Some 513 citations were obtained from the initial electronic search strategy in late 1997, the full text of 89 of which were sought for detailed assessment. Hand searching of reference lists and books resulted in a further 27 reports being retrieved. Of this total of 116 reports, 16 were review articles, 2 were case studies, 7 were irrelevant articles not involving lecithin, 6 were letters about or re-analyses of studies of tacrine (THA) combined with lecithin and 1 was a letter about the biochemistry of lecithin. The remaining 84 reports are listed under included or excluded studies.<BR/>
<BR/>Subsequent searches, conducted in February 2000, May 2002 and May 2004 yielded no additional trials. A further excluded study was added in February 2000 (<LINK REF="STD-Sahakian-1987" TYPE="STUDY">Sahakian 1987</LINK>) and three further excluded studies in August 2002 (<LINK REF="STD-Jones-1990" TYPE="STUDY">Jones 1990</LINK>, <LINK REF="STD-Pomara-1983b" TYPE="STUDY">Pomara 1983b</LINK>, <LINK REF="STD-Schmechel-1984" TYPE="STUDY">Schmechel 1984</LINK>, <LINK REF="STD-Smith-1982" TYPE="STUDY">Smith 1982</LINK>). A study that was previously pending (<LINK REF="STD-Panijel-1986" TYPE="STUDY">Panijel 1986</LINK>) was incorporated into the review in August 2000.</P>
<P>Twelve randomized trials were identified of lecithin versus placebo (or no treatment) in patients suffering from dementia or cognitive impairment. These comprise the included studies. The most common reasons for exclusion were a lack of concurrent control (i.e. open cohort studies), a controlled trial with no evidence of randomization, or a confounding of lecithin with another active treatment.</P>
<P>Thirty reports were identified relating to the twelve included trials.</P>
<P>See: Characteristics of Included Studies</P>
<P>
<B>STUDY DESIGN</B>
<BR/>Seven parallel group and five crossover trials have been identified. A total of 376 patients was randomized to receive lecithin or placebo in the UK (75 patients), the USA (115 patients), Canada (96 patients) and Germany (90 patients). All reports were published between 1981 and 1993, six of the trials having primary publications during 1981 or 1982.</P>
<P>
<B>PARTICIPANTS</B>
<BR/>Ten trials studied patients with Alzheimer's disease, one dealt with dementia associated with Parkinson's disease (<LINK REF="STD-Garcia-1982" TYPE="STUDY">Garcia 1982</LINK>) and one involved people with subjective memory complaints (<LINK REF="STD-Panijel-1986" TYPE="STUDY">Panijel 1986</LINK>). Ages ranged approximately from 47 to 89, and approximately 60% were female. Where severity of dementia was reported it ranged from 'mild' (<LINK REF="STD-Etienne-1981" TYPE="STUDY">Etienne 1981</LINK>) to 'moderate to severe' (<LINK REF="STD-Fisman-1981" TYPE="STUDY">Fisman 1981</LINK>). The <LINK REF="STD-Levy-1983" TYPE="STUDY">Levy 1983</LINK> study examined early cases of senile dementia of the Alzheimer type, that of <LINK REF="STD-Heyman-1987" TYPE="STUDY">Heyman 1987</LINK> was concerned with early-onset dementia and that of <LINK REF="STD-Uney-1992" TYPE="STUDY">Uney 1992</LINK> with elderly people.</P>
<P>
<B>INTERVENTIONS</B>
<BR/>Doses of lecithin ranged from 1 g/day to 35 g/day, though the concentration of phosphatidylcholine in the lecithin varied between 25% and 95%. Treatment periods ranged from one week in the crossover trial of <LINK REF="STD-Brinkman-1982" TYPE="STUDY">Brinkman 1982</LINK> to 2 years in the trial of <LINK REF="STD-Crapper-McLachlan" TYPE="STUDY">Crapper McLachlan</LINK>. Lecithin was administered in a wide variety of forms including milk-shakes, biscuits, soups and aqueous solutions. Eleven trials used a placebo; the <LINK REF="STD-Crapper-McLachlan" TYPE="STUDY">Crapper McLachlan</LINK> trial had a no-treatment arm but no placebo.</P>
<P>
<B>OUTCOME MEASURES</B>
<BR/>The majority of outcome measures were scales, mostly for aspects of cognition. All outcomes identified in the trials are listed in Characteristics of Included Studies. The following published scales have been extracted for analyses in this review:</P>
<P>Global Impression:<BR/>SCAG-G, Sandoz Clinical Assessment - Geriatric: global score (<LINK REF="REF-Shader-1974" TYPE="REFERENCE">Shader 1974</LINK>)</P>
<P>Functional Performance:<BR/>PADL, Performance of Activities of Daily Living (<LINK REF="REF-Kuriansky-1976" TYPE="REFERENCE">Kuriansky 1976</LINK>)<BR/>CWS, Cornell Weighted Scale (<LINK REF="REF-McDowell-1971" TYPE="REFERENCE">McDowell 1971</LINK>)</P>
<P>Behaviour:<BR/>SCAG-T, Sandoz Clinical Assessment - Geriatric: total not including global score (<LINK REF="REF-Shader-1974" TYPE="REFERENCE">Shader 1974</LINK>)</P>
<P>Cognition:<BR/>PALT, Paired Associate Learning Test (<LINK REF="REF-Inglis-1959" TYPE="REFERENCE">Inglis 1959</LINK>)<BR/>MSQ, Mental State Questionnaire (<LINK REF="REF-Kahn-1960" TYPE="REFERENCE">Kahn 1960</LINK>)</P>
<P>In addition, <LINK REF="STD-Crapper-McLachlan" TYPE="STUDY">Crapper McLachlan</LINK> used a novel technique of video assessment of behaviour, <LINK REF="STD-Levy-1983" TYPE="STUDY">Levy 1983</LINK> created a scale for orientation, <LINK REF="STD-Garcia-1982" TYPE="STUDY">Garcia 1982</LINK> used their own memory scale, <LINK REF="STD-Heyman-1987" TYPE="STUDY">Heyman 1987</LINK> reduced results to dichotomous variables for global clinical impression and for cognition, and <LINK REF="STD-Panijel-1986" TYPE="STUDY">Panijel 1986</LINK> used tests described by <LINK REF="REF-Oswald-1982" TYPE="REFERENCE">Oswald 1982</LINK> and their own global change scale. These tests included attention (similar to Trail A, <LINK REF="REF-War-Dept-1944" TYPE="REFERENCE">War Dept 1944</LINK>), immediate memory (digit span), subjective memory complaints and global impression. These have also been included in analyses of this review. We have as yet been unable to obtain the report of <LINK REF="REF-Oswald-1982" TYPE="REFERENCE">Oswald 1982</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>RANDOMIZATION</B>
<BR/>All included trials were described as randomized, though an attempt to describe the randomization process was provided only for the <LINK REF="STD-Dysken-1982" TYPE="STUDY">Dysken 1982</LINK> trial. In this trial, a sequence of allocations was determined by coin flip, and bottles which did not indicate their contents were prepared by a pharmacist. Code A (adequate concealment allocation) was assigned to this trial; code B (unclear concealment) was assigned to all other trials.<BR/>
<BR/>In the <LINK REF="STD-Crapper-McLachlan" TYPE="STUDY">Crapper McLachlan</LINK> trial, patients were "randomly assigned" to lecithin, no treatment and desferrioxamine in the ratio 9:14:25. No explanation was given of the unequal allocation. On discovering no clear differences between the lecithin and no treatment groups, the trialists combined them into a group of 23 for analysis purposes. </P>
<P>
<B>BLINDING</B>
<BR/>All but one of the trials (<LINK REF="STD-Crapper-McLachlan" TYPE="STUDY">Crapper McLachlan</LINK>) were described as double-blind. In the <LINK REF="STD-Crapper-McLachlan" TYPE="STUDY">Crapper McLachlan</LINK> trial, assessors of video-recorded behaviour were blind to treatment allocation. Only this outcome (and death which is not subject to observer bias) contribute to the review from this trial.</P>
<P>
<B>FOLLOW-UP</B>
<BR/>Numbers of drop-outs and withdrawals from the studies were largely available. Among the six reports relating to the <LINK REF="STD-Levy-1983" TYPE="STUDY">Levy 1983</LINK> trial, two fully reported early results on 30 of the 51 completers and two reported means and ANOVA results from all completers. Since standard deviations were not available from the latter two reports, results in this review are based on the 30 early completers.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Few trial reports provided data able to contribute to meta-analyses. No trials reported data on dependency, quality of life or the effect on carers. We present results separately for patients with Alzheimer's disease, Parkinsonian dementia and subjective memory complaints.</P>
<P>ALZHEIMER'S DISEASE<BR/>All trials reported equivocal results, i.e. no demonstrated effect of lecithin, for the outcomes addressed in this review, though there is some evidence that lecithin increases plasma choline levels (see tables).</P>
<P>Global impression<BR/>Two trials reported on some measure of global impression of change. They produced a pooled odds ratio estimate of 3.0 (95% confidence interval (CI) from 0.9 to 9.8), a just non-significant finding in favour of placebo. Heterogeneity was not significant according to the standard chi-square test, but these results are based on a random effects analysis since the test would have minimal power to detect heterogeneity. A fixed effect analysis gives the same quantitative conclusion but with very slightly narrower CIs.</P>
<P>Functional performance<BR/>
<LINK REF="STD-Levy-1983" TYPE="STUDY">Levy 1983</LINK> found a relative deterioration on lecithin of 0.8 points (-0.9 to 2.4) on the Performance on Activities of Daily Living (PADL) scale, though this did not approach statistical significance. </P>
<P>Behaviour<BR/>Two trials found a consistent lack of effect on behavioural scales, yielding a standardized mean difference of 0.09 (-0.6 to 0.8), with no discernible heterogeneity.</P>
<P>Cognition<BR/>
<LINK REF="STD-Heyman-1987" TYPE="STUDY">Heyman 1987</LINK> assessed overall cognition in Alzheimer's disease in terms of worsened/improved, finding no difference (Odds Ratio (OR) = 0.9, 95% CI 0.3 to 3.3). As components of cognition, no difference was found between lecithin and placebo for either memory as assessed by the Uncategorized Recognition test, or orientation as assessed by the Mental State Questionnaire or by the <LINK REF="STD-Levy-1983" TYPE="STUDY">Levy 1983</LINK> questionnaire. <LINK REF="STD-Dysken-1982" TYPE="STUDY">Dysken 1982</LINK> and <LINK REF="STD-Levy-1983" TYPE="STUDY">Levy 1983</LINK> both used the Paired Associates Learning Test (PALT). There was heterogeneity between their results (chi-square = 3.8 on 1 d.f.) and a random effects analysis gave a standardized mean difference of -0.03 (-1.5 to 1.4). <LINK REF="STD-Dysken-1982" TYPE="STUDY">Dysken 1982</LINK> had found a non-significant difference in favour of placebo over two weeks; <LINK REF="STD-Levy-1983" TYPE="STUDY">Levy 1983</LINK> had found an almost significant difference in favour of lecithin over six months. Standardized mean differences are used here due to the large difference in treatment periods. For the same reason, it may not be appropriate to pool these results.</P>
<P>Death<BR/>Deaths were enumerable from three trials. Since no deaths occurred during the appropriate periods of the <LINK REF="STD-Dysken-1982" TYPE="STUDY">Dysken 1982</LINK> and <LINK REF="STD-Uney-1992" TYPE="STUDY">Uney 1992</LINK> trials, these do not contribute to a meta-analysis using odds ratios. Fewer deaths were observed in the lecithin group of the <LINK REF="STD-Crapper-McLachlan" TYPE="STUDY">Crapper McLachlan</LINK> trial (1/9) than in the no treatment group (4/14); reasons were not given.</P>
<P>Withdrawals and adverse events<BR/>In the <LINK REF="STD-Levy-1983" TYPE="STUDY">Levy 1983</LINK> trial, 14/34 reported side-effects from the lecithin group and 9/34 dropped out whereas 3/29 reported side-effects in the placebo group and 3/29 dropped out. Neither the nature of the side-effects nor the reasons for drop-out were reported. The difference between side-effects rates was statistically significant in favour of placebo (OR = 6, 95% CI 1.5 to 24).</P>
<P>Reported bottom line<BR/>Since so few data were available for analysis in this review, the basic conclusion of each trial has been extracted (see tables) as further evidence regarding the efficacy of lecithin relative to placebo or no treatment.</P>
<P>PARKINSONIAN DEMENTIA<BR/>The single trial of <LINK REF="STD-Garcia-1982" TYPE="STUDY">Garcia 1982</LINK> that involved patients with Parkinsonian dementia found no evidence of an effect of lecithin on functional performance. They found a statistically significant improvement in their memory test, though this was not a standard test, and a slight, non-significant, improvement in orientation. One patient from each group reported an adverse event.</P>
<P>PEOPLE WITH SUBJECTIVE MEMORY COMPLAINTS<BR/>The trial of <LINK REF="STD-Panijel-1986" TYPE="STUDY">Panijel 1986</LINK> involved 90 subjects with subjective memory complaints (brain organic psychosyndrome with predominantly memory and concentration disturbances). The mean age of subjects was 55 years. Subjects were selected as having subjective symptoms of memory disturbance and scoring greater than 30 seconds on the "ZVT" test, a test very similar to Trail A (<LINK REF="REF-War-Dept-1944" TYPE="REFERENCE">War Dept 1944</LINK>). Highly statistically significant differences between the treatment groups were observed. The lecithin treatment group improved from a mean of 49.2 seconds to 37.6 seconds whereas the placebo group only changed from 48.7 seconds to 47.9 seconds (mean difference in final measurements of 10.3 (95% CI from 6.3 to 14.3). A global assessment scale, ranging from 0 to 3, yielded a mean difference of 1.6 (95% CI from 1.35 to 1.85) in favour of lecithin, which would appear to be a highly clinically significant benefit. Similarly striking benefits of lecithin were recorded in other tests. </P>
<P>Apart from the division of trials into those addressing Alzheimer's disease, Parkinsonian dementia and cognitive impairment, no subgroup analyses were performed due to the lack of an appropriate volume of data.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Despite the widespread belief that lecithin may have some role in the treatment of patients with Alzheimer's disease, relatively few patients have participated in randomized trials of lecithin and the data extractable from the published reports are few. Furthermore, the studies are diverse in terms of the types of participants, including severity of dementia, the dose of lecithin administered and the selection of outcomes.</P>
<P>Even allowing for these qualifications, there is no suggestion of a significant beneficial effect of lecithin on the memory performance of subjects with Alzheimer's disease. As evidenced by the conclusions of these reports, the investigators' opinions were almost unanimous concerning the lack of significant clinical effect. One of the more rigorous studies, <LINK REF="STD-Levy-1983" TYPE="STUDY">Levy 1983</LINK>, found some evidence of benefit in one test of memory but in view of the multiple comparisons the significance of this is uncertain.</P>
<P>We are unsure how to interpret the results of the Panijel study on people with subjective memory disturbance who would not fulfil any current criteria for cognitive impairment. This is the only trial on this topic, and the only trial to report a significant benefit of lecithin. Furthermore, the results were dramatic but only in tests of attention and subjective symptoms. Some external confirmation of the role of lecithin in such patients is warranted, using standardized cognitive scales of memory and other functions.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>On the basis of the published studies there is no evidence to support the use of lecithin in the treatment of patients with dementia. A single trial has produced dramatic results in favour of lecithin for people with memory complaints (brain organic psychosyndrome), but this needs to be replicated before conclusions can be drawn.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a lack of large randomized trial evidence evaluating the use of lecithin in the treatment of people with dementia and therefore a modest treatment effect may have been missed. The lack of a suggestion of significant benefit from the small published trials would not indicate priority for the performance of larger studies in Alzheimer's disease. There is a need to evaluate the role of lecithin in people with subjective memory complaints in the light of a single trial producing significant results. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>With grateful thanks to Jacqueline Birks and Reinhard Wentz for translation help, Dymphna Hermans for undertaking searching and members of the Cochrane Dementia and Cognitive Improvement Group editorial team for advice and support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>-Both reviewers designed the protocol, selected papers to be retrieved, selected studies for inclusion and extracted data. Information from one paper, in German, was extracted separately by Jacqueline Birks in conjunction with JH and by Reinhard Wentz in conjunction with JH. The first draft of the text was written, and the analyses were entered, by JH. LF added missing sections and commented on the rest.</P>
<P>-This review has been peer reviewed anonimously by two peer reviewers (November 2002).</P>
<P>JH: minor update (August 2004)<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>The study in German was incorporated into the review in August 2000. This introduced new conclusions for a new type of subject with subjective memory disturbances, but conclusions for Alzheimer's disease and dementia are unaltered.</P>
<P>August 2002: four excluded studies were added; the search strategy section was updated as well as the sections on contributions and acknowledgements.</P>
<P>November 2002: the review has now been peer reviewed. No changes were made.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Brinkman-1982" NAME="Brinkman 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brinkman SD, Pomara N, Goodnick PJ, et al</AU>
<TI>A dose-ranging study of lecithin in the treatment of primary degenerative dementia (Alzheimer disease)</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>4</NO>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Pomara N, Goodnick PJ, Brinkman SD, et al</AU>
<TI>A dose-response study of lecithin in the treatment of Alzheimer's disease</TI>
<SO>Alzheimer's Disease: A Report of Progress</SO>
<YR>1982</YR>
<PG>379-83</PG>
<ED>Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crapper-McLachlan" NAME="Crapper McLachlan" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF</AU>
<TI>Intramuscular desferrioxamine in patients with Alzheimer's disease [published erratum appears in Lancet 1991 Jun 29; 337(8757):1618]</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<PG>1304-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crapper McLachlan DR, Smith WL, Kruck TP</AU>
<TI>Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>1993</YR>
<VL>15</VL>
<PG>602-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kruck TP, Fisher EA, McLachlan DR</AU>
<TI>Prediction of side effects in Alzheimer's disease patients on longterm deferoxamine-mesylate treatment</TI>
<SO>Alzheimer's disease and related disorders: advances in the biosciences</SO>
<YR>1993a</YR>
<VL>87</VL>
<PG>257-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kruck TPA/Fisher EA, McLachlan DR</AU>
<TI>A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylate</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1993b</YR>
<VL>53</VL>
<NO>1</NO>
<PG>30-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McLachlan DR, Fraser PE, Dalton AJ</AU>
<TI>Aluminium and the pathogenesis of Alzheimer's disease: a summary of evidence</TI>
<SO>Aluminium in biology and medicine (Ciba Foundation Symposium)</SO>
<YR>1992</YR>
<VL>169</VL>
<PG>87-98; discussion 99-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>McLachlan DR, Kruck TP, Smith WL</AU>
<TI>Aluminium chelation therapy of Alzheimer's disease</TI>
<SO>Alzheimer disease: therapeutic strategies</SO>
<YR>1994</YR>
<PG>328-33</PG>
<ED>Giacobini E, Becker R</ED>
<PB>Birkhauser</PB>
<CY>Boston</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dysken-1982" NAME="Dysken 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Dysken MW, Foval P, Harris CM, et al</AU>
<TI>Lecithin administration in patients with primary degenerative dementia and normal volunteers</TI>
<SO>Alzheimer's Disease: A Report of Progress</SO>
<YR>1982</YR>
<PG>385-92</PG>
<ED>Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dysken MW, Fovall P, Harris CM, Davis JM, Noronha A</AU>
<TI>Lecithin administration in Alzheimer dementia [letter]</TI>
<SO>Neurology</SO>
<YR>1982</YR>
<VL>32</VL>
<PG>1203-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Harris, CM</AU>
<SO>Test on the Memory-Enhancing Effect of Phosphatidylcholine in Humans [PhD thesis]</SO>
<YR>1997</YR>
<PB>University of Illinois at Chigago. Health Sciences Center</PB>
<CY>Chigago</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etienne-1981" NAME="Etienne 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Etienne P, Dastoor D, Gauthier S, Ludwick R, Collier B</AU>
<TI>Alzheimer disease: lack of effect of lecithin treatment for 3 months</TI>
<SO>Neurology</SO>
<YR>1981</YR>
<VL>31</VL>
<PG>1552-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Etienne P, Dastoor D, Gauthier S, et al</AU>
<TI>Lecithin in the treatment of Alzheimer's disease</TI>
<SO>Alzheimer's Disease: A Report of Progress</SO>
<YR>1982</YR>
<PG>369-72</PG>
<ED>Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gauthier S, Etienne P, Dastoor D, et al</AU>
<TI>Lack of effect of a 3-month treatment with lecithin in Alzheimer disease</TI>
<SO>Neurology</SO>
<YR>1981</YR>
<VL>31</VL>
<PG>89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nair NPV, Gauthier S, Etienne P, et al</AU>
<TI>Lack of effect of a 3 month treatment with lecithin in Alzheimer's disease</TI>
<SO>Progress in Neuro-Psychopharmacology</SO>
<YR>1981</YR>
<VL>5</VL>
<PG>305-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisman-1981" NAME="Fisman 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fisman M</AU>
<TI>Double blind study of lecithin in patients with Alzheimer's disease</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>26</VL>
<PG>426-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-1982" NAME="Garcia 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Garcia CA, Tweedy JR, Blass JP, et al</AU>
<TI>Lecithin and Parkinsonian dementia</TI>
<SO>Alzheimer's Disease: A Report of Progress</SO>
<YR>1982</YR>
<PG>443-9</PG>
<ED>Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tweedy JR, Garcia CA</AU>
<TI>Lecithin treatment of cognitively impaired Parkinson's patients</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1982</YR>
<VL>12</VL>
<PG>87-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heyman-1982" NAME="Heyman 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Heyman A, Logue P, Wilkinson W, et al</AU>
<TI>Lecithin therapy of Alzheimer's disease</TI>
<SO>Alzheimer's Disease: A Report of Progress</SO>
<YR>1982</YR>
<PG>373-8</PG>
<ED>Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heyman-1987" NAME="Heyman 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heyman A, Schmechel D, Wilkinson W, Rogers H, Krishnan R, Holloway D, Schultz K, Gwyther L, Peoples R, Utley C, et al</AU>
<TI>Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease</TI>
<SO>Journal of Neural Transmission Suppl</SO>
<YR>1987</YR>
<VL>24</VL>
<PG>279-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1983" NAME="Levy 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chuaqui P, Levy R</AU>
<TI>Fluctuations of free choline levels in plasma of Alzheimer patients receiving lecithin: preliminary observations</TI>
<SO>British Journal Of Psychiatry</SO>
<YR>1982</YR>
<VL>140</VL>
<PG>464-9</PG>
<PB>British Journal Of Psychiatry</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy R, Little A, Chuaqui P, Reith M</AU>
<TI>Early results from double-blind, placebo controlled trial of high dose phosphatidylcholine in Alzheimer's disease [letter]</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>1</VL>
<PG>987-8</PG>
<PB>Lancet</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy R, Little A, Chuaqui P, Reith M</AU>
<TI>The effects of long-term administration of lecithin on the course of Alzheimer senile dementia</TI>
<SO>Interdisciplinary Topics in Gerontology</SO>
<YR>1985</YR>
<VL>20</VL>
<PG>153-66</PG>
<PB>Interdisciplinary Topics in Gerontology</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Little A, Chuaqui Kidd P, Levy R</AU>
<TI>Early results from a double-blind, placebo-controlled trial of high dose lecithin in Alzheimer's disease: psychometric test performance, plasma choline levels and the effects of drug compliance</TI>
<SO>Alzheimer's Disease: Advances in Basic Research and Therapies</SO>
<YR>1984</YR>
<PG>313-32</PG>
<ED>Wurtman RJ, Corkin H, Growdon JH</ED>
<PB>Alzheimer's Disease</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Little A, Levy R, Chuaqui Kidd P, Hand D</AU>
<TI>A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1985</YR>
<VL>48</VL>
<PG>736-42</PG>
<PB>Journal of Neurology, Neurosurgery and Psychiatry</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Little A</AU>
<TI>Evaluating treatments for dementia: lessons from the Maudsley Lecithin trial</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>293-304</PG>
<PB>International Journal of Geriatric Psychiatry</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panijel-1986" NAME="Panijel 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Panijel M</AU>
<TI>Effect of lecithin in disorders of memory, learning and concentration</TI>
<TO>Therapeutische Wirksamkeit von Lecithin bei Gedachtnis-und Konzentrationsstorungen</TO>
<SO>Therapiewoche</SO>
<YR>1986</YR>
<VL>36</VL>
<PG>5029-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uney-1992" NAME="Uney 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Uney JB, Jones GM, Rebeiro A, Levy R</AU>
<TI>The effect of long-term high dose lecithin on erythrocyte choline transport in Alzheimer patients</TI>
<SO>Biological Psychiatry</SO>
<YR>1992</YR>
<VL>31</VL>
<PG>630-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vroulis-1982" NAME="Vroulis 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Vroulis G, Johnson R, Morgan R</AU>
<TI>Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1984</YR>
<VL>20</VL>
<PG>542-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vroulis G, Smith RC, Schoolar JC, et al</AU>
<TI>Reduction of cholesterol risk factors by lecithin in patients with Alzheimer's disease</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<PG>1633-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Antoine-1986" NAME="Antoine 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antoine M, Holland C, Scruggs B</AU>
<TI>Measuring improvement in patients with dementia</TI>
<SO>Geriatric Nursing</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>185-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbeau-1978a" NAME="Barbeau 1978a" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbeau A</AU>
<TI>Emerging treatments: replacement therapy with choline or lecithin in neurological diseases</TI>
<SO>Canadian Journal of Neurological Science</SO>
<YR>1978</YR>
<VL>5</VL>
<PG>157-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbeau-1978b" NAME="Barbeau 1978b" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbeau A</AU>
<TI>Lecithin in neurologic disorders [letter]</TI>
<SO>New England Jounal of Medicine</SO>
<YR>1978</YR>
<VL>299</VL>
<PG>200-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbeau-1980" NAME="Barbeau 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbeau A</AU>
<TI>Lecithin in Parkinson's disease</TI>
<SO>Journal of Neural Transmission Suppl</SO>
<YR>1980</YR>
<VL>187-93</VL>
<PG>187-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Battye-1982" NAME="Battye 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Battye D, Chuaqui P, Little A, et al</AU>
<TI>The effect of choline on neurophysiological measurements. A preliminary report on four normal subjects</TI>
<SO>Journal of Electrophysiological Technology</SO>
<YR>1982</YR>
<VL>8</VL>
<PG>176-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borromei-1985" NAME="Borromei 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borromei A, Gaggi R, Giancola LC</AU>
<TI>Involutional dementias: new perspectives</TI>
<SO>Italian Journal of Neurological Science</SO>
<YR>1985</YR>
<VL>6</VL>
<PG>167-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branconnier-1984" NAME="Branconnier 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branconnier RJ, Dessain EC, Cole JO, McNiff Langille ME</AU>
<TI>An analysis of dose-response of plasma choline to oral lecithin</TI>
<SO>Biological Psychiatry</SO>
<YR>1984</YR>
<VL>19</VL>
<PG>765-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brinkman-1982b" NAME="Brinkman 1982b" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brinkman SD, Smith RC, Meyer JS, Vroulis G, Shaw T, Gordon JR, Allen RH</AU>
<TI>Lecithin and memory training in suspected Alzheimer's disease</TI>
<SO>Journal of Gerontology</SO>
<YR>1982</YR>
<VL>37</VL>
<PG>4-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caine-1980" NAME="Caine 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caine ED</AU>
<TI>Cholinomimetic treatment fails to improve memory disorders [letter]</TI>
<SO>New England Journal of Medicine</SO>
<YR>1980</YR>
<VL>303</VL>
<PG>585-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canter-1982" NAME="Canter 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canter NI, Hallett M, Growdon JH</AU>
<TI>Lecithin does not affect EEG spectral analysis or P-300 in Alzheimer disease</TI>
<SO>Neurology</SO>
<YR>1982</YR>
<VL>32</VL>
<PG>1260-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christie-1979" NAME="Christie 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Christie JE, Blackburn IM, Glen AIM, et al</AU>
<TI>Effects of choline and lecithin on CSF choline levels and on cognitive function in patients with presenile dementia of the Alzheimer type</TI>
<SO>Nutrition and the Brain</SO>
<YR>1979</YR>
<PG>377-87</PG>
<ED>Barbeau A, Growdon JH, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Christie JE, Glen AIM, Yates CM, et al</AU>
<TI>Choline and lecithin effects on CSF choline levels and on cognitive function in Alzheimer pre-senile dementia</TI>
<SO>Alzheimer's Disease. Early Recognition of Potential Reversible Deficits</SO>
<YR>1979</YR>
<PG>163-8</PG>
<ED>Glen AIM, Whalley LJ</ED>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corkin-1981" NAME="Corkin 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corkin S</AU>
<TI>Lecithin precursor treatment in alzheimers-disease and amnesic syndromes</TI>
<SO>International Journal Of Neuroscience</SO>
<YR>1981</YR>
<VL>12</VL>
<PG>178</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corser-1979" NAME="Corser 1979" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Corser CM, Baikie E, Brown E</AU>
<TI>Effect of lecithin in senile dementia: a report of four cases</TI>
<SO>Alzheimer's Disease. Early Recognition of Potential Reversible Deficits</SO>
<YR>1979</YR>
<PG>169-72</PG>
<ED>Glen AIM, Whalley LJ</ED>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1987" NAME="Davidson 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Mohs RC, Hollander E, Zemishlany Z</AU>
<TI>Lecithin and piracetam in Alzheimer's disease</TI>
<SO>Biological Psychiatry</SO>
<YR>1987</YR>
<VL>22</VL>
<PG>112-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Domino-1982" NAME="Domino 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Domino EF, Minor L, Duffy IF, et al</AU>
<TI>Effects of oral lecithin on blood choline and memory tests in geriatric volunteers</TI>
<SO>Alzheimer's Disease: A Report of Progress</SO>
<YR>1982</YR>
<PG>393-7</PG>
<ED>Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drachman-1982" NAME="Drachman 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drachman DA, Glosser G, Fleming P, Longenecker G</AU>
<TI>Memory decline in the aged - treatment with high-dose lecithin</TI>
<SO>Neurology</SO>
<YR>1981</YR>
<VL>31</VL>
<PG>101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drachman DA, Glosser G, Fleming P, Longenecker G</AU>
<TI>Memory decline in the aged: treatment with lecithin and physostigmine</TI>
<SO>Neurology</SO>
<YR>1982</YR>
<VL>32</VL>
<PG>944-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapen S, Fleming PD, Drachman DA</AU>
<TI>Cholinergic enhancement and REM sleep latency in the aged: lecithin does not reproduce physostigmine effect</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36</VL>
<PG>1079-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duffy-1987" NAME="Duffy 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duffy FH, McAnulty G, Albert M, Durwen H, Weintraub S</AU>
<TI>Lecithin: absence of neurophysiologic effect in Alzheimer's disease by EEG topography</TI>
<SO>Neurology</SO>
<YR>1987</YR>
<VL>37</VL>
<PG>1015-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etienne-1979" NAME="Etienne 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Etienne P, Gauthier S, Dastoor D, Collier B, Ratner J</AU>
<TI>Lecithin in Alzheimer's disease [letter]</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>2</VL>
<PG>1206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Etienne P, Gauthier S, Dastoor D, et al</AU>
<TI>Alzheimer's disease: clinical effect of lecithin treatment</TI>
<SO>Nutrition and the Brain</SO>
<YR>1979</YR>
<PG>389-96</PG>
<ED>Barbeau A, Growdon JH, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Etienne P, Gauthier S, Dastoor D, et al</AU>
<TI>Alzheimer's disease: clinical effect of lecithin treatment</TI>
<SO>Alzheimer's Disease. Early Recognition of Potential Reversible Deficits</SO>
<YR>1979</YR>
<PG>173-8</PG>
<ED>Glen AIM, Whalley LJ</ED>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitten-1990" NAME="Fitten 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitten LJ, Perryman KM, Gross PL, Fine H, Cummins J, Marshall C</AU>
<TI>Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<PG>239-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perryman KM, Fitten LJ</AU>
<TI>Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease</TI>
<SO>Life Sciences</SO>
<YR>1993</YR>
<VL>53</VL>
<PG>479-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forsell-1989" NAME="Forsell 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forssell LG, Sjokvist B, Winblad B</AU>
<TI>Early stages of late onset Alzheimer's disease. III. Double blind treatment with choline chloride and lecithin with and without L-dopa and L-tryptophan, alternatively placebo</TI>
<SO>Acta Neurologica Scandinavica Suppl</SO>
<YR>1989</YR>
<VL>79</VL>
<PG>43-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Growdon-1978" NAME="Growdon 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Growdon JH, Gelenberg AJ, Hirsch MJ, Wurtman RJ</AU>
<TI>Lecithin can supress tardive dyskinesia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1978</YR>
<VL>298</VL>
<PG>1029-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Growdon-1984" NAME="Growdon 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Growdon JH, Wheeler S, Graham HN</AU>
<TI>Plasma choline responses to lecithin-enriched soup</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1984</YR>
<VL>20</VL>
<PG>603-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Growdon-1986" NAME="Growdon 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Growdon JH, Corkin S, Huff FJ, Rosen TJ</AU>
<TI>Piracetam combined with lecithin in the treatment of Alzheimer's disease</TI>
<SO>Neurobiology of Aging</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>269-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Growdon JH, Corkin S, Huff FJ</AU>
<TI>Clinical evaluation of compounds for the treatment of memory dysfunction</TI>
<SO>Memory Dysfunctions: An Integration of Animal and Human Research From Preclinical and Clinical Perspectives</SO>
<YR>1985</YR>
<PG>437-49</PG>
<ED>Olton DS, Gamzu E, Corkin S</ED>
<PB>New York Academy of Sciences</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hallett-1982" NAME="Hallett 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallett M, Canter N, Growdon J</AU>
<TI>Neurophysiologic parameters in alzheimer-disease - effect of lecithin</TI>
<SO>Neurology</SO>
<YR>1982</YR>
<VL>32</VL>
<PG>A126</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenike-1986" NAME="Jenike 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Albert MS, Heller H, LoCastro S, Gunther J</AU>
<TI>Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<PG>249-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1990" NAME="Jones 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Jones GMM</AU>
<TI>The cholinergic hypothesis of dementia: the effects of lecithin and nicotine on human memory and attention in Dementia of the Alzheimer type (PhD thesis)</TI>
<SO>University of London</SO>
<YR>1990</YR>
<MD>Cochrane Dementia and Cognitive Improvement Group</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaye-1982" NAME="Kaye 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaye WH, Sitaram N, Weingartner H, et al</AU>
<TI>Modest facilitation of memory in dementia with combined lecithin and anticholinerestase treatment</TI>
<SO>Biological Psychiatry</SO>
<YR>1982</YR>
<VL>17</VL>
<PG>275-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kazdova-1984" NAME="Kazdova 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kazdova E</AU>
<TI>Treatment of dementia with high doses of lecithin and piracetam</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1984</YR>
<VL>26</VL>
<PG>244-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kushnir-1987" NAME="Kushnir 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kushnir SL, Ratner JT, Gregoire PA</AU>
<TI>Multiple nutrients in the treatment of Alzheimer's disease</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1987</YR>
<VL>35</VL>
<PG>476-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladd-1993" NAME="Ladd 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ladd SL, Sommer SA, Laberge S, Toscano W</AU>
<TI>Effect of phosphatidylcholine on explicit memory</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1993</YR>
<VL>16</VL>
<PG>540-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lampe-1990" NAME="Lampe 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lampe TH, Norris J, Risse SC, Owenwilliams E, Keenan T</AU>
<TI>Therapeutic potential of thyrotropin-releasing-hormone (trh) and lecithin coadministration in alzheimers-disease</TI>
<SO>Neurobiology of Aging</SO>
<YR>1990</YR>
<VL>11</VL>
<PG>346</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neri-1985" NAME="Neri 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neri M, Pirani A, Dinelli M, Belloi L</AU>
<TI>Phosphatidylcholine dietary-intake and senile dementia</TI>
<SO>Acta Therapeutica</SO>
<YR>1985</YR>
<VL>11</VL>
<PG>49-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1979" NAME="Peters 1979" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perryman KM, Fitten LJ</AU>
<TI>Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease</TI>
<SO>Life Sciences</SO>
<YR>1993</YR>
<VL>53</VL>
<PG>479-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters BH, Levin HS</AU>
<TI>Effects of physostigmine and lecithin on memory in Alzheimer disease</TI>
<SO>Annals Of Neurology</SO>
<YR>1979</YR>
<VL>6</VL>
<PG>219-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1981" NAME="Peters 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters BH</AU>
<TI>Memory augmentation following physostigmine or physostigmine plus lecithin administration in amnesic syndrome and alzheimers-disease</TI>
<SO>International Journal Of Neuroscience</SO>
<YR>1981</YR>
<VL>12</VL>
<PG>178</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1982" NAME="Peters 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin HS, Peters BH</AU>
<TI>Long-term administration of oral physostigmine and lecithin improve memory in alzheimers-disease</TI>
<SO>Annals Of Neurology</SO>
<YR>1984</YR>
<VL>15</VL>
<PG>210</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Peters BH, Levin HS</AU>
<TI>Chronic oral physostigmine and lecithin administration in memory disorders of the aging</TI>
<SO>Alzheimer's Disease: A Report of Progress</SO>
<YR>1982</YR>
<PG>421-6</PG>
<ED>Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pomara-1983a" NAME="Pomara 1983a" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pomara N, Domino EF, Yoon H, Brinkman S, Tamminga CA, Gershon S</AU>
<TI>Failure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1983</YR>
<VL>44</VL>
<PG>293-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pomara-1983b" NAME="Pomara 1983b" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Pomara N, Block R, Abraham J et al.</AU>
<TI>Combined cholinergic precursor treatment and dihydroergotoxine mesylate in Alzheimer's disease</TI>
<SO>IRCS Journal of Medical Science</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>12</NO>
<PG>1048-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sahakian-1987" NAME="Sahakian 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sahakian B, Joyce E, Lishman WA</AU>
<TI>Cholinergic effects on constructional abilities and on mnemonic processes: a case report</TI>
<SO>Psychological Medicine</SO>
<YR>1987</YR>
<VL>17</VL>
<PG>329-333</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samorajski-1985" NAME="Samorajski 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Samorajski T, Vroulis GA, Smith RC</AU>
<TI>Piracetam plus lecithin trials in senile dementia of the Alzheimer type</TI>
<SO>Memory Dysfunctions: An Integration of Animal and Human Research From Preclinical and Clinical Perspectives</SO>
<YR>1985</YR>
<PG>478-81</PG>
<ED>Olton DS, Gamzu E, Corkin S</ED>
<PB>New York Academy of Sciences</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Vroulis G, Johnson R, Morgan R</AU>
<TI>Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1984</YR>
<VL>20</VL>
<PG>542-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmechel-1984" NAME="Schmechel 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Schmechel DE, Schmitt F, Horner J, Wilkinson WE, Hurwitz BJ, Heyman A</AU>
<TI>Lack of effect of oral physostigmine and lecithin in patients with probable Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<NO>Suppl 1</NO>
<PG>280</PG>
<MD>Cochrane Dementia and Cognitive Improvement Group</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1982" NAME="Smith 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Smith RC, Ho BT, Hsu L et al.</AU>
<TI>Cholinesterase enzymes in the blood of patients with Alzheimer's disease</TI>
<SO>Life Sciences</SO>
<YR>1982</YR>
<VL>30</VL>
<NO>6</NO>
<PG>543-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorgatz-1987" NAME="Sorgatz 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Sorgatz H</AU>
<TI>Effects of lecithin on memory and learning</TI>
<SO>Lecithin: Technological, Biological and Therapeutic Aspects</SO>
<YR>1987</YR>
<PG>147-53</PG>
<ED>Hann I, Ansell GB</ED>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sullivan-1982" NAME="Sullivan 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Sullivan EV, Shedlock KJ, Corkin S, et al</AU>
<TI>Physostigmine and lecithin in Alzheimer's disease</TI>
<SO>Alzheimer's Disease: A Report of Progress</SO>
<YR>1982</YR>
<PG>361-7</PG>
<ED>Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thal-1986" NAME="Thal 1986" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Fuld PA, Masur DM, Sharpless NS, Davies P</AU>
<TI>Oral physostigmine and lecithin improve memory in Alzheimer's disease</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1983</YR>
<VL>19</VL>
<PG>454-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Fuld PA, Masur DM, Sharpless NS</AU>
<TI>Long-term administration of oral physostigmine and lecithin improve memory in Alzheimers-disease - reply</TI>
<SO>Annals Of Neurology</SO>
<YR>1984</YR>
<VL>15</VL>
<PG>210</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Fuld PA, Masur DM, Sharpless NS</AU>
<TI>Oral physostigmine and lecithin improve memory in Alzheimer disease</TI>
<SO>Annals Of Neurology</SO>
<YR>1983</YR>
<VL>13</VL>
<PG>491-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Masur DM, Sharpless NS, Fuld PA, Davies P</AU>
<TI>Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>1986</YR>
<VL>10</VL>
<PG>627-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tudorache-1990" NAME="Tudorache 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tudorache B, Lupulescu R, Dutan I, Sarbulescu A</AU>
<TI>Assessment of various psychopharmacological combinations in the treatment of presenile and senile primary degenerative dementia</TI>
<SO>Romanian Journal of Neurology and Psychiatry</SO>
<YR>1990</YR>
<VL>28</VL>
<PG>277-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinarova-1987" NAME="Vinarova 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinarova E, Vinar O</AU>
<TI>Lecithin in a psychiatric out-patient clini</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1987</YR>
<VL>29</VL>
<NO>29th Annual Psychopharmacology Meeting (1987, Jesenik, Czechoslovakia)</NO>
<PG>219-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vroulis-1981" NAME="Vroulis 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vroulis GA, Smith RC, Brinkman S, Schoolar J, Gordon J</AU>
<TI>The effects of lecithin on memory in patients with senile dementia of the Alzheimer's type</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1981</YR>
<VL>17</VL>
<PG>127-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vroulis-1983" NAME="Vroulis 1983" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vroulis GA, Johnson R, Morgan R, Smith RC</AU>
<TI>Piracetam and lecithin in Alzheimers-disease</TI>
<SO>Age</SO>
<YR>1983</YR>
<VL>6</VL>
<PG>136</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weintraub-1983" NAME="Weintraub 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weintraub S, Mesulan MM, Auty R, Baratz R, Cholakos BN, Kapust L, Ransil B, Tellers JG, Albert MS, LoCastro S, et al</AU>
<TI>Lecithin in the treatment of Alzheimer's disease [letter]</TI>
<SO>Archives of Neurology</SO>
<YR>1983</YR>
<VL>40</VL>
<PG>527-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wettstein-1982" NAME="Wettstein 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wettstein A</AU>
<TI>No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease</TI>
<TO>Doppelblinder, Plazebo-kontrollierter Therapieversuch mit Lecithin und Physostigmin bei Morbus Alzheimer</TO>
<SO>Schweizen Archiv fur Neurologie, Neurochirurgie und Psychiatrie</SO>
<YR>1982</YR>
<VL>131</VL>
<PG>223-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders: DSM-IV</SO>
<YR>1994</YR>
<PG>American Psychiatric Association, 1994</PG>
<EN>Fourth</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bramer-1988" NAME="Bramer 1988" TYPE="JOURNAL_ARTICLE">
<AU>Bramer GR</AU>
<TI>International statistical classification of diseases and related health problems. Tenth revision</TI>
<SO>World Health Statistics Quarterly</SO>
<YR>1988</YR>
<VL>41</VL>
<PG>32-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inglis-1959" NAME="Inglis 1959" TYPE="JOURNAL_ARTICLE">
<AU>Inglis J</AU>
<TI>Learning, retardation and conceptual usage in elderly patients with memory disorders</TI>
<SO>Journal of Abnormal Psychology</SO>
<YR>1959</YR>
<VL>59</VL>
<PG>210-215</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kahn-1960" NAME="Kahn 1960" TYPE="JOURNAL_ARTICLE">
<AU>Kahn RL, Goldfarb AI, Pollack M, Peek A</AU>
<TI>Brief objective measures for the determination of mental status in the aged</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1960</YR>
<VL>117</VL>
<PG>326-328</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kunz-2002" NAME="Kunz 2002" TYPE="COCHRANE_REVIEW">
<AU>Kunz R, Vist G, Oxman AD</AU>
<TI>Randomisation to protect against selection bias in healthcare trials (Cochrane Methodology Review)</TI>
<TO>Randomisation to protect against selection bias in healthcare trials (Cochrane Methodology Review)</TO>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuriansky-1976" NAME="Kuriansky 1976" TYPE="JOURNAL_ARTICLE">
<AU>Kuriansky JB, Gurland BJ, Fleiss JL, Cowan D</AU>
<TI>The assessment of self-care capacity in geriatric psychiatric patients by objective and subjective methods</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>1976</YR>
<VL>32</VL>
<PG>96-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDowell-1971" NAME="McDowell 1971" TYPE="BOOK_SECTION">
<AU>McDowell FH, Markham CH, Lee JE, Treciokas LJ, Ansel RO</AU>
<TI>The clinical use of levodopa in the treatment of Parkinson's disease</TI>
<SO>Recent Advances in Parkinson's Disease</SO>
<YR>1971</YR>
<PG>175-201</PG>
<ED>McDowell FH, Markham CH</ED>
<PB>FA Davis Co.</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKhann-1984" NAME="McKhann 1984" TYPE="JOURNAL_ARTICLE">
<AU>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM</AU>
<TI>Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>939-944</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oswald-1982" NAME="Oswald 1982" TYPE="BOOK_SECTION">
<AU>Oswald WD, Fleischmann UM</AU>
<TI>Nurnberger-Alters-Inventar NAI</TI>
<TO>Nurnberger-Alters-Inventar NAI</TO>
<SO>Nurnberger-Alters-Inventar NAI</SO>
<YR>1982</YR>
<PB>Universitat Erlangen-Nurnberg</PB>
<CY>Nurnberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shader-1974" NAME="Shader 1974" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Shader RI, Harmatz JS, Salzman C</AU>
<TI>A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment-Geriatric (SCAG)</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1974</YR>
<VL>22</VL>
<PG>107-113</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-War-Dept-1944" NAME="War Dept 1944" TYPE="OTHER">
<TI>Army individual test battery: Manual of directions and scoring</TI>
<SO>Washington DC War Department Adjuvant General's Office</SO>
<YR>1944</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehead-1994" NAME="Whitehead 1994" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead A, Jones NMB</AU>
<TI>A meta-analysis of clinical trials involving different classifications of response into ordered categories</TI>
<SO>Statistics in Medicine</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>2503-2515</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wurtman-1977" NAME="Wurtman 1977" TYPE="JOURNAL_ARTICLE">
<AU>Wurtman RJ, Hirsch MJ, Growdon JH</AU>
<TI>Lecithin consumption raises serum-free-choline levels</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>2</VL>
<PG>68-69</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-04 14:37:35 +0000" MODIFIED_BY="Helen Collins">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-04 14:37:35 +0000" MODIFIED_BY="Helen Collins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Brinkman-1982">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, crossover trial in two phases (separately randomized); one week of treatment on each dose/placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 in- and outpatients with primary degenerative dementia (AD), diagnosed by DSM III criteria:<BR/>Age range 65-82 years; 8 female, 2 male<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Phase1 :<BR/>1. Lecithin (95% PC) 4 g/day<BR/>2. Lecithin 12 g/day<BR/>3. Lecithin 20 g/day<BR/>4. Placebo<BR/>Phase 2:<BR/>1. Lecithin best dose<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Buschke Selective Reminding Test, Organizational Memory Test, Wechsler Memory Scale, choline levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No data extractable from first period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Crapper-McLachlan">
<CHAR_METHODS>
<P>Randomized, single-blind, controlled, parallel group trial; behavioural outcome raters blinded to treatment allocation; two years of treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 outpatients with probable AD, diagnosed by NINCDS-ADRDA criteria, of whom 23 eligible for this review: <BR/>Average age 63 years (SD 6.2); 12 female, 11 male<BR/>Location: Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin 1 g/day (n=9)<BR/>2. No treatment (n=14)<BR/>3. Desferrioxamine (n=25)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Video recorded home behaviour measures, Wechsler Adult Intelligence Scale-revised, Wechsler Memory Scale, Western Aphasia Battery, London Psychogeriatric Rating Scale</P>
<P>Death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data contributed: <BR/>1. Behaviour: video recorded home behaviour (rate of deterioration - regression on repeated scores)<BR/>2. Death</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dysken-1982">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, crossover trial; 2 weeks of treatment on each dose/placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 outpatients and 5 inpatients with SDAT, diagnosed by non-standard criteria:<BR/>Age range 54-87; 8 female, 7 male; variable severity (from mild to severe)<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment schedule (only first period used in this review):<BR/>1. Lecithin (25% PC) 15 g/day - Lecithin 22.5 g/day - Lecithin 30 g/day - Placebo (n=8)<BR/>2. Placebo - Lecithin 15 g/day - Lecithin 22.5 g/day - Lecithin 30 g/day (n=7)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Face-Hand Test, Mental Status Questionnaire (MSQ), Paired Associates Learning Test (PALT), Trials-A, Categorized Recognition, Uncategorized Recognition (URG), Categorized Recall, Unrecognized Recall, Adjective Checklist, Hamilton Rating Scale for Depression, Sandoz Clinical Assessment - Geriatric (SCAG-T and SCAG-G)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Both reports by Dysken (1982) describe the 10 outpatients; this review includes the additional 5 inpatients, with individual patient data obtained from the PhD thesis by Harris (1981)<BR/>Data contributed :<BR/>1. Global Impression : SCAG-G (dichotomised to no improvement/improvement in average score between baseline and first treatment period)<BR/>2. Behaviour: SCAG-T ([first period mean - baseline mean])<BR/>3. Cognition ([first period mean - baseline mean]): Memory (URG, since all but one patients provided data); Learning/memory (PALT); Orientation (MSQ)<BR/>4. Death</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Etienne-1981">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, crossover trial; 3 months of treatment on each of lecithin/placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>15 outpatients with progressive dymnesia (probable AD), diagnosed by non-standard criteria:<BR/>Age range 47-85 years; 'mild' or 'moderate' severity<BR/>Location: Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin (55% PC) 30 g/day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wechsler Memory Scale (digit span), Benton Visual Retention Test, Logical Memory Test, Milner Facial Recognition Test, Paired Associate Learning Test, subjective impression of family members, choline levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>4 subjects excluded between randomisation and analysis;<BR/>No data extractable from first period - except that no subject suffered any adverse events at any time</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fisman-1981">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, parallel group trial; 8 weeks of treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>33 inpatients with AD, diagnosed by non-standard criteria:<BR/>Age range 61-89 years; 24 female, 9 male; 'moderate' to 'severe' severity<BR/>Location: Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin 15 g/day (1 week) - 20 g/day (1 week) - 25 g/day (6 weeks)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>London Psychogeriatric Rating Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No data extractable for analysis since numbers randomised to the two groups are not given.<BR/>Deaths: lecithin 1, placebo 2<BR/>Withdrawals/drop-outs: lecithin 6, placebo 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Garcia-1982">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, parallel group trial; 9 weeks of treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>21 outpatients with Parkinson's disease and exhibiting evidence of intellectual impairment or reporting episodes of confusion or disorientation; reports only address the 16 who completed:<BR/>Age range 56-84; 4 female, 12 male<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin (25% PC) 32.4 g/day (n=8)<BR/>2. Placebo (n=8)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cornell Weighted Scale (CWS), Purdue pegboard, mobility of upper arm, memory test, written arithmetic test, verbal fluency test, Wechsler Adult Intelligence Scale, Raven's Coloured Progressive Matrices, Symbol Digit Modalities test, Mental Status Questionnaire (MSQ)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>16 of the 21 randomized patients are described in the published reports. Changes in scores from baseline are reported<BR/>Data contributed (all signs reversed so that low change-score is good):<BR/>1. Functional performance: CWS (functional disability items)<BR/>2. Components of Cognition: Short-term memory (memory test), Orientation (MSQ)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Heyman-1982">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, crossover trial; 8 weeks of treatment on each dose/placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 outpatients with AD, diagnosed by non-standard criteria:<BR/>Age range 50-69; 12 female, 6 male; 'mild' to 'moderate' severity<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin (53% PC) 25g/day<BR/>2. Lecithin 40 g/day<BR/>3. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mini-Mental State Evaluation, Digit Span, Category Retrieval, Aphasia Screening Test, Verbal Paired-Associate Learing Test, Trailmaking Tests A &amp; B, Visuospatial Ability, Digit Symbol</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only a preliminary report from this trial, detailing the first 12 patients to have completed; No extractable data from first period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Heyman-1987">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, parallel group trial; 6 months of treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 outpatients with early onset of probable AD (before age 70), diagnosed by non-standard criteria:<BR/>Mean age 63 years; 'mild' to 'moderate' severity<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin (18 g of PC/day)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mini-Mental State Examination, Buscke Selective Reminding Test, Spatial Memory Test, Wepman Aphasia Screening Test, Verbal Fluency Test, Lawton assessment of instrumental activities of daily living, Clinical Dementia Rating, Blessed Test, Writing Proficiency Scale, Hamilton Rating Scale for Depression, choline levels<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data presented in published report are collapsed into the following two dichotomous outcomes; results are available only for 37 patients who completed the trial.<BR/>Data contributed:<BR/>1. Global Impression (clinical outcome)<BR/>2. Cognition (neuropsychological changes)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Levy-1983">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, parallel group trial; 6 months of treatment, 6 months of drug-free follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>63 patients with early SDAT, diagnosed by non-standard criteria:<BR/>Mean age 74 years; at least 21 female, at least 9 male; mild or moderate severity ('early' dementia)<BR/>Location: UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin (90% PC) 20-25g/day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Paired Associate Learning Test (PALT), Verbal fluency, Orientation questionnaire (OQ), Kew Tests, Incomplete Letters, Cube Analysis, Digit Copy Test, Coloured Progressive Matrices, Perfomance on Activities of Daily Living (PADL), Informant ratings, Abbreviated Mental Test Score, Forced Choice Faces, Forced Choice Words</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>12 patients dropped out during the 6-month treatment period; test scores with standard deviations are only available from reports of early results (n=30); continuous outcomes are change-from-baseline measures; signs have been reversed so that a low change-score is good<BR/>Data contributed:<BR/>1. Functional performance: PADL<BR/>2. Components of Cognition: Memory (PALT), Orientation (OQ)<BR/>3. Withdrawals<BR/>4. Adverse events (side effects)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Panijel-1986">
<CHAR_METHODS>
<P>Randomized, double blind, placebo-controlled, parallel group trial; 2 weeks of washout post randomization followed by 8 weeks of treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>90 people with subjective memory complaints (brain organic psychosyndrome with predominantly memory and concentration disturbances)<BR/>Mean age 55 years; 60 female, 30 male; 'mild' to 'moderate' severity<BR/>Location: Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin (Buerlecithin) 2 fascicles 3 times a day (n=45)<BR/>2. Placebo (n=45)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Four tests from Nurnberger-Alters-Inventar (number combination test, old age self assessment scale, old age questionnaire, immediate memory test), Global assessment (scale 0-3)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Translated from German<BR/>Data contributed:<BR/>1. Global assessment<BR/>2. Cognition (Immediate Memory; Attention (number combination test similar to Trail A))</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Uney-1992">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, parallel group trial; 18 weeks of treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 patients with AD, dignosed by NINCDS-ADRDA:<BR/>Age range over 75<BR/>Location: UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin 15 g/day (n=6)<BR/>2. Placebo (n=6)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Biochemical outcomes only</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No clinical outcomes described, but no deaths occurred</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vroulis-1982">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, crossover trial; 5 months of treatment on each of lecithin/placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>11 patients with DAT, diagnosed by non-standard criteria:<BR/>Age range 50-76 years, at least 4 female, at least 6 male; variable severity<BR/>Location: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Lecithin (53% PC) 35 g/day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Buschke Selective Reminding Procedure, Halstead-Wepman Aphasia Screening Test, Pfeifer Mental Status Exam, Dementia Rating Scale, biochemical outcomes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No data extractable from first period, but no deaths occurred</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AD - Alzheimer's disease<BR/>DAT - Dementia of the Alzheimer type<BR/>SDAT - Senile dementia of the Alzheimer type<BR/>DSM - Diagnostic and Statistical Manual (of Mental Disorders)<BR/>NINCDS-ADRA - National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association<BR/>PC - Phosphatidylcholine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Antoine-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin with physostigmine in 9 patients with mental deficits</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barbeau-1978a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 12 patients with Friedreich's ataxia, Marie's ataxia or olivoponto-cerebellar atrophy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barbeau-1978b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 21 patients with tardive dyskinesia, Huntington's chorea, spastic spinocerebellar degeneration or Friedreich's ataxia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barbeau-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 10 patients with Parkinson's disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Battye-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of lecithin versus placebo in 4 healthy volunteers; no indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Borromei-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized trial of lecithin, S-adenosylmethionine or both in 10 patients with various types of dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Branconnier-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, double-blind, trial of lecithin (10g, 20g, 40g/day; 53% PC) versus placebo in 56 healthy subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brinkman-1982b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of lecithin (35g/day; 53% PC) versus placebo in 10 patients with AD; memory training given towards end of lecithin periods; no indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caine-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin with pilocarpine in 2 patients with disordered memory</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Canter-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 10 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Christie-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 12 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Corkin-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind trial of lecithin and physostigmine in patients with presenile dementia and healthy elderly subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Corser-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 4 patients with senile dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davidson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, double-blind, trial of lecithin (confounded) with piracetam versus placebo in 10 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Domino-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, double-blind, trial of lecithin (&lt;100g/week; 22% PC) versus placebo in 20 geriatric volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Drachman-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, double-blind, trial of lecithin (26g/day; 95% PC) versus placebo in 18 healthy subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duffy-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of lecithin (best of 10g,15g,20g/day; 95% PC) versus placebo in 10 patients with AD; no indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Etienne-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 7 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fitten-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, double-blind, trial of tacrine versus placebo in 10 patients with AD; everyone receiving lecithin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Forsell-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind trial of lecithin (confounded) with choline chloride versus placebo in 18 patients with dementia; no indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Growdon-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 3 patients with tardive dyskinesia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Growdon-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 9 patients with AD, 8 patients with tardive dyskinesia and 2 healthy subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Growdon-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trials of lecithin, piracetam and placebo in patients with AD; no direct comparison of lecithin and placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hallett-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 10 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jenike-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of lecithin (confounded) with ergoloid mesylates versus placebo in 7 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double blind studies of lecithin and nicotine including 24 patients with AD. No indication of randomization. Thesis assessed by editorial base, not current reviewers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaye-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, factorial design, trial of tacrine, lecithin and placebo in 10 patients with primary degenerative dementia; treatment for one day only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kazdova-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin with piracetam in 10 patients with dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kushnir-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin, tryptophan and tyrosine in 8 patients with primary degenerative dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ladd-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized, double-blind, trial of lecithin versus placebo in 80 healthy subjects; treatment for one day only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lampe-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, double-blind, trial of thyrotropin-releasing hormone versus placebo in 6 patients with AD; everyone receiving lecithin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neri-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 12 patients with dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peters-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, double-blind, trial of lecithin versus physostigmine versus both in 5 patients with AD; no placebo or no treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peters-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind trial of physostigmine versus physostigmine with lecithin in 8 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peters-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, double-blind, trial of physostigmine versus placebo in 9 patients with AD; everyone receiving lecithin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pomara-1983a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin (single dose) in 6 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pomara-1983b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind placebo controlled crossover trial of lecithin (20g/day, 95% PC) versus placebo in 9 patients with AD all receiving hydergine. No indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sahakian-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind placebo controlled n-of-1 trial of physostigmine versus placebo, with a period of lecithin following the trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Samorajski-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of lecithin (confounded) with piracetam versus placebo in 11 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmechel-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind placebo controlled crossover trial of physostigmine versus placebo in 12 patients with AD; everyone receiving lecithin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind placebo controlled crossover trial of lecithin (35g/day, 53% PC) versus placebo in 17 patients with dementia. No indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sorgatz-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, double-blind, trial of lecithin (9 g/day) versus placebo in 58 healthy subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sullivan-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of lecithin (30 g/day or 20 g/day; 55% or 80% PC) versus placebo in 18 patients with AD; no indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thal-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of physostigmine versus placebo in 16 patients with AD; everyone receiving lecithin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tudorache-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of piracetam versus neostigmine versus centrophenoxine in 90 patients with primary degenerative dementia; everyone receiving lecithin; no indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vinarova-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of lecithin in 42 patients with mild AD, obstipation, endogenous depression, Sjogren's syndrome, xerostomia or tardive dyskinesia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vroulis-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of lecithin (35 g/day; 53% PC) versus placebo in 18 patients with AD; no indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vroulis-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of piracetam versus placebo in 10 patients with AD; everyone receiving lecithin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weintraub-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind crossover trial of lecithin versus placebo in 13 patients with AD; no indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wettstein-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind trial of lecithin (confounded) with physostigmine versus placebo in 8 patients with AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>For some studies, lecithin dose is given together with the percentage of phosphatidylcholine (PC) in the lecithin</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-11-04 14:37:35 +0000" MODIFIED_BY="Helen Collins">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-11-04 14:37:35 +0000" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-04 14:38:23 +0000" MODIFIED_BY="Helen Collins">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Lecithin versus Control (Alzheimer's disease)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Dependency</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.943093053354142" CI_END="9.809760218824788" CI_START="0.9219224733421043" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.0072975249934837" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.9916583919962636" LOG_CI_START="-0.03530559826888134" LOG_EFFECT_SIZE="0.4781763968636912" METHOD="MH" NO="2" P_CHI2="0.3314838224356452" P_Q="0.0" P_Z="0.06797050757568544" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="28" WEIGHT="99.99999999999999" Z="1.825202295297608">
<NAME>Global impression</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="122.57001767183473" CI_START="0.7107048915040522" EFFECT_SIZE="9.333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="2.088384248713186" LOG_CI_START="-0.14831069546807266" LOG_EFFECT_SIZE="0.9700367766225568" ORDER="93599" O_E="0.0" SE="1.313845682030609" STUDY_ID="STD-Dysken-1982" TOTAL_1="8" TOTAL_2="7" VAR="1.726190476190476" WEIGHT="21.08127721335268"/>
<DICH_DATA CI_END="8.410024837490466" CI_START="0.5871887063786416" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.9247972784101745" LOG_CI_START="-0.23122230596086166" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="93600" O_E="0.0" SE="0.6790516262487787" STUDY_ID="STD-Heyman-1987" TOTAL_1="16" TOTAL_2="21" VAR="0.4611111111111111" WEIGHT="78.91872278664731"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.434715824880869" CI_START="-0.9147158248808693" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.76" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.37376237173111737" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.8894479923818728">
<NAME>Functional performance</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.434715824880869" CI_START="-0.9147158248808693" EFFECT_SIZE="0.76" ESTIMABLE="YES" MEAN_1="1.85" MEAN_2="1.09" ORDER="93601" SD_1="2.51" SD_2="2.17" SE="0.8544625503788916" STUDY_ID="STD-Levy-1983" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.001255663759832583" CI_END="0.7657567068624412" CI_START="-0.5770825254102235" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0943370907261089" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.9717326031849657" P_Q="1.0" P_Z="0.783022287373996" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="19" UNITS="" WEIGHT="100.00000000000001" Z="0.2753826307510167">
<NAME>Behaviour</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0003799977901457" CI_START="-0.7902887324071727" EFFECT_SIZE="0.10504563269148659" ESTIMABLE="YES" MEAN_1="1.83" MEAN_2="1.64" ORDER="93602" SD_1="1.51" SD_2="1.86" SE="0.45681164152042714" STUDY_ID="STD-Crapper-McLachlan" TOTAL_1="8" TOTAL_2="12" WEIGHT="56.23640405420697"/>
<CONT_DATA CI_END="1.0955099246161686" CI_START="-0.9343567857008724" EFFECT_SIZE="0.08057656945764803" ESTIMABLE="YES" MEAN_1="-2.63" MEAN_2="-3.5" ORDER="93603" SD_1="11.49" SD_2="8.35" SE="0.5178326556835663" STUDY_ID="STD-Dysken-1982" TOTAL_1="8" TOTAL_2="7" WEIGHT="43.76359594579304"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3405158004970783" CI_START="0.24740079986113456" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.5238135302889302" LOG_CI_START="-0.6065989006053805" LOG_EFFECT_SIZE="-0.04139268515822506" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.8858658578830308" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="21" WEIGHT="100.0" Z="0.1435372965057422">
<NAME>Cognition</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3405158004970783" CI_START="0.24740079986113456" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.5238135302889302" LOG_CI_START="-0.6065989006053805" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="93604" O_E="0.0" SE="0.6640098575390962" STUDY_ID="STD-Heyman-1987" TOTAL_1="16" TOTAL_2="21" VAR="0.4409090909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.487571973780681" CI_END="0.4657256881478432" CI_START="-0.5956450168211432" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.06495966433665001" ESTIMABLE="YES" I2="38.34365127406871" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.16557520082744992" P_Q="0.5271613190981452" P_Z="0.8103972827011355" Q="1.2804974442781507" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1382372580290796" TOTALS="SUB" TOTAL_1="51" TOTAL_2="49" UNITS="" WEIGHT="300.0" Z="0.23991354189743785">
<NAME>Components of Cognition</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.462653291022939" CI_START="-0.6616663316865948" DF="0.0" EFFECT_SIZE="0.40049347966817217" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.45989745844599805" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="7" WEIGHT="99.99999999999999" Z="0.7390157185400827">
<NAME>Memory</NAME>
<CONT_DATA CI_END="1.462653291022939" CI_START="-0.6616663316865948" EFFECT_SIZE="0.40049347966817217" ESTIMABLE="YES" MEAN_1="0.15" MEAN_2="-0.29" ORDER="93605" SD_1="0.94" SD_2="1.11" SE="0.541928229157754" STUDY_ID="STD-Dysken-1982" TOTAL_1="7" TOTAL_2="7" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.82560809244615" CI_END="1.4173925479210583" CI_START="-1.48232095947969" DF="1.0" EFFECT_SIZE="-0.03246420577931584" ESTIMABLE="YES" I2="73.86036478816142" ID="CMP-001.07.02" NO="2" P_CHI2="0.05047507599373957" P_Z="0.9649951316417621" STUDIES="2" TAU2="0.8229538234205638" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="0.043886179756559285">
<NAME>Learning/Memory (PALT)</NAME>
<CONT_DATA CI_END="2.113049454319341" CI_START="-0.4862854320889861" EFFECT_SIZE="0.8133820111151774" ESTIMABLE="YES" MEAN_1="1.75" MEAN_2="-3.36" ORDER="93606" SD_1="5.44" SD_2="5.89" SE="0.6631078190496226" STUDY_ID="STD-Dysken-1982" TOTAL_1="4" TOTAL_2="7" WEIGHT="32.71611835258214"/>
<CONT_DATA CI_END="0.06120707881096965" CI_START="-1.420011302641138" EFFECT_SIZE="-0.6794021119150843" ESTIMABLE="YES" MEAN_1="-0.44" MEAN_2="1.43" ORDER="93607" SD_1="2.8" SD_2="2.53" SE="0.3778687754305103" STUDY_ID="STD-Levy-1983" TOTAL_1="16" TOTAL_2="14" WEIGHT="67.28388164741786"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.38146643705638" CI_END="0.6031366299230101" CI_START="-0.8361390849800241" DF="1.0" EFFECT_SIZE="-0.11650122752850703" ESTIMABLE="YES" I2="27.613152721191426" ID="CMP-001.07.03" NO="3" P_CHI2="0.23985171266492922" P_Z="0.7510190164047903" STUDIES="2" TAU2="0.07978509599760043" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.0" Z="0.31729599512622014">
<NAME>Orientation</NAME>
<CONT_DATA CI_END="0.4493699739148753" CI_START="-1.6390884780375687" EFFECT_SIZE="-0.5948592520613467" ESTIMABLE="YES" MEAN_1="-0.44" MEAN_2="0.21" ORDER="93608" SD_1="1.12" SD_2="0.91" SE="0.5327798032070838" STUDY_ID="STD-Dysken-1982" TOTAL_1="8" TOTAL_2="7" WEIGHT="39.2483262683462"/>
<CONT_DATA CI_END="0.8839995343532507" CI_START="-0.5533529727572013" EFFECT_SIZE="0.16532328079802472" ESTIMABLE="YES" MEAN_1="0.75" MEAN_2="0.07" ORDER="93609" SD_1="3.59" SD_2="4.43" SE="0.36667829573607097" STUDY_ID="STD-Levy-1983" TOTAL_1="16" TOTAL_2="14" WEIGHT="60.75167373165381"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Effect on carer</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.377774898515619" CI_START="0.02891141444710113" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.5286307039709485" LOG_CI_START="-1.5389306606107602" LOG_EFFECT_SIZE="-0.505149978319906" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.3382023564100922" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="27" WEIGHT="100.0" Z="0.9577232204650995">
<NAME>Death</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.377774898515619" CI_START="0.02891141444710113" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5286307039709485" LOG_CI_START="-1.5389306606107602" LOG_EFFECT_SIZE="-0.505149978319906" ORDER="93610" O_E="0.0" SE="1.2144957801491119" STUDY_ID="STD-Crapper-McLachlan" TOTAL_1="9" TOTAL_2="14" VAR="1.475" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93611" O_E="0.0" SE="0.0" STUDY_ID="STD-Dysken-1982" TOTAL_1="8" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93612" O_E="0.0" SE="0.0" STUDY_ID="STD-Uney-1992" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.872932250849647" CI_START="0.7561913486616467" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.1200000000000006" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="1.1096774836033343" LOG_CI_START="-0.12136829556644858" LOG_EFFECT_SIZE="0.49415459401844286" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.11560311075086885" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="29" WEIGHT="100.0" Z="1.5734999030244567">
<NAME>Withdrawal</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.872932250849647" CI_START="0.7561913486616467" EFFECT_SIZE="3.12" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.1096774836033343" LOG_CI_START="-0.12136829556644858" LOG_EFFECT_SIZE="0.4941545940184428" ORDER="93613" O_E="0.0" SE="0.7231223844592165" STUDY_ID="STD-Levy-1983" TOTAL_1="34" TOTAL_2="29" VAR="0.5229059829059829" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.996241511573347E-32" CI_END="24.029672834590716" CI_START="1.5316248663803878" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="6.066666666666666" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="1.380747857899232" LOG_CI_START="0.18515240863159257" LOG_EFFECT_SIZE="0.7829501332654123" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.010257899801754004" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="29" WEIGHT="100.0" Z="2.5670122177715435">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="24.029672834590716" CI_START="1.5316248663803878" EFFECT_SIZE="6.066666666666666" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="1.380747857899232" LOG_CI_START="0.18515240863159257" LOG_EFFECT_SIZE="0.7829501332654123" ORDER="93614" O_E="0.0" SE="0.7022986851927343" STUDY_ID="STD-Levy-1983" TOTAL_1="34" TOTAL_2="29" VAR="0.49322344322344325" WEIGHT="100.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.12" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO">
<NAME>Reported conclusions</NAME>
<TR>
<TH>
<P>Reported conclusion</P>
</TH>
<TH>
<P>Source</P>
</TH>
</TR>
<OTHER_DATA ORDER="1129" STUDY_ID="STD-Brinkman-1982">
<TR>
<TD>
<P>"These results are in agreement with other controlled studies that have failed to demonstrate a significant improvement in mean scores with lecithin therapy in SDAT"</P>
</TD>
<TD>
<P>1st line of Dicussion, Brinkman (1982)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="1130" STUDY_ID="STD-Crapper-McLachlan">
<TR>
<TD>
<P>"There were no differences in the rate of deterioration of patients receiving either placebo [lecithin] or no treatment"</P>
</TD>
<TD>
<P>Abstract, Crapper McLachlan (1991)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="1131" STUDY_ID="STD-Dysken-1982">
<TR>
<TD>
<P>"We did not find any significant drug main effect on any cognitive measure during either the dose-ranging study or the replication study...We conclude that lecithin did not result in any clinically significant improvement in cognitive functioning"</P>
</TD>
<TD>
<P>letter to Neurology, Dysken (1982)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="1132" STUDY_ID="STD-Etienne-1981">
<TR>
<TD>
<P>"Plasma choline levels rose threefold and remained at that level throughout the lecithin administration...However, there were no differences between mean placebo and lecithin scores on any of the psychological test measures"</P>
</TD>
<TD>
<P>Abstract, Etienne (1991)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="1133" STUDY_ID="STD-Fisman-1981">
<TR>
<TD>
<P>"Equal improvement was noted in both lecithin and placebo groups...Serum levels...were also not increased"</P>
</TD>
<TD>
<P>Abstract, Fisman (1981)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="1134" STUDY_ID="STD-Heyman-1982">
<TR>
<TD>
<P>"In this preliminary trial...no major improvements were noted in social behaviour, activities of daily living, on in the mean scores of a batery of psychologic tests for short-term memory, orientation, or verbal communication"</P>
</TD>
<TD>
<P>1st line of Summary, Heyman (1982)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="1135" STUDY_ID="STD-Heyman-1987">
<TR>
<TD>
<P>"Lecithin therapy produced an increase in mean plasma choline levels...it appears that lecithin alone has no important therapeutic effect in early-onset Alzheimer's disease"</P>
</TD>
<TD>
<P>Abstract, Heyman (1987)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="1136" STUDY_ID="STD-Levy-1983">
<TR>
<TD>
<P>"There were no differences between the placebo group and the lecithin group but there was an improvement in a subgroup of relatively poor compliers"</P>
</TD>
<TD>
<P>Abstract, Little (1985)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="1137" STUDY_ID="STD-Uney-1992">
<TR>
<TD>
<P>"Administration of lecithin to AD patients caused an elevation in plasma and erythrocyte choline concentrations"</P>
</TD>
<TD>
<P>Discussion, Uney (1992)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="1138" STUDY_ID="STD-Vroulis-1982">
<TR>
<TD>
<P>The results from our study indicate that even long-term lecithin treatment has small if any effect on improving memory functions in patients with DAT"</P>
</TD>
<TD>
<P>1st line of Discussion, Smith (1984)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-11-04 14:38:23 +0000" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Lecithin versus Control (Parkinsonian dementia)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Dependency</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Global impression</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="12.406386304371797" CI_START="-10.406386304371797" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8635708609312891" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.17183040554998974">
<NAME>Functional performance</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.406386304371797" CI_START="-10.406386304371797" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-1.3" ORDER="93625" SD_1="15.56" SD_2="5.37" SE="5.8196917873715615" STUDY_ID="STD-Garcia-1982" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Behaviour</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cognition</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.1807876017301817" CI_END="0.07597839072403256" CI_START="-2.275978390724032" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" I2="15.31076388888888" I2_Q="15.31076388888888" ID="CMP-002.07" MODIFIED="2008-11-04 14:38:23 +0000" MODIFIED_BY="Helen Collins" NO="7" P_CHI2="0.27719576997755613" P_Q="0.27719576997755613" P_Z="0.06675301517123747" Q="1.1807876017301817" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.11023749999999992" TOTALS="SUB" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="199.99999999999997" Z="1.8333333333333333">
<NAME>Components of Cognition</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1695172218696801" CI_START="-3.2304827781303196" DF="0.0" EFFECT_SIZE="-1.7" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="1.0" P_Z="0.029476776529445657" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="99.99999999999999" Z="2.177050811240412">
<NAME>Memory</NAME>
<CONT_DATA CI_END="-0.1695172218696801" CI_START="-3.2304827781303196" EFFECT_SIZE="-1.7" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="1.4" ORDER="93626" SD_1="1.41" SD_2="1.7" SE="0.7808729089935186" STUDY_ID="STD-Garcia-1982" TOTAL_1="8" TOTAL_2="8" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0304827781303199" CI_START="-2.03048277813032" DF="0.0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" MODIFIED="2008-11-04 14:38:23 +0000" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.0" P_Z="0.5219716942057309" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="99.99999999999999" Z="0.640309062129533">
<NAME>Orientation</NAME>
<CONT_DATA CI_END="1.0304827781303199" CI_START="-2.03048277813032" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="0.1" ORDER="93627" SD_1="1.41" SD_2="1.7" SE="0.7808729089935186" STUDY_ID="STD-Garcia-1982" TOTAL_1="8" TOTAL_2="8" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Effect on carer</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.59444130963117" CI_START="0.048811525792669376" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="1.219962635459375" LOG_CI_START="-1.3114776165807254" LOG_EFFECT_SIZE="-0.045757490560675115" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.9435128852151631" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="0.07085534288204409">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.59444130963117" CI_START="0.048811525792669376" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.219962635459375" LOG_CI_START="-1.3114776165807254" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="93628" O_E="0.0" SE="1.4869805348796974" STUDY_ID="STD-Garcia-1982" TOTAL_1="11" TOTAL_2="10" VAR="2.2111111111111112" WEIGHT="100.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-002.12" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Reported conclusions</NAME>
<TR>
<TH>
<P>Reported conclusion</P>
</TH>
<TH>
<P>Source</P>
</TH>
</TR>
<OTHER_DATA ORDER="1143" STUDY_ID="STD-Garcia-1982">
<TR>
<TD>
<P>"Marked clinical improvement was not observed, but some indications of a positive treatment effect were obtained on memory, cognition, and motility tests."</P>
</TD>
<TD>
<P>Abstract, Tweedy (1982)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Lecithin versus Control (subjective memory complaints)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Dependency</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.8479180129218244" CI_START="1.3520819870781753" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.131483790198662E-36" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="100.0" Z="12.649110640673516">
<NAME>Global impression</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lecithin</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8479180129218244" CI_START="1.3520819870781753" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="1.2" ORDER="93630" SD_1="0.6" SD_2="0.6" SE="0.12649110640673517" STUDY_ID="STD-Panijel-1986" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Functional performance</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Behaviour</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cognition</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="16.904647819837077" CI_END="14.07549825638397" CI_START="-2.360709896595613" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.857394179894178" ESTIMABLE="YES" I2="94.0844671201814" I2_Q="94.0844671201814" ID="CMP-003.07" NO="7" P_CHI2="3.930547646846527E-5" P_Q="3.930547646846527E-5" P_Z="0.16242856540129996" Q="16.904647819837077" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="33.193000000000104" TOTALS="SUB" TOTAL_1="90" TOTAL_2="90" UNITS="" WEIGHT="200.0" Z="1.3969501394719137">
<NAME>Components of Cognition</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lecithin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0039236633185951E-30" CI_END="2.3343481448928576" CI_START="1.4656518551071418" DF="0.0" EFFECT_SIZE="1.8999999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-003.07.01" NO="1" P_CHI2="0.0" P_Z="1.0029070452935037E-17" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="8.57360993574566">
<NAME>Immediate Memory</NAME>
<CONT_DATA CI_END="2.3343481448928576" CI_START="1.4656518551071416" EFFECT_SIZE="1.8999999999999995" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="4.9" ORDER="93631" SD_1="1.1" SD_2="1.0" SE="0.2216102685145955" STUDY_ID="STD-Panijel-1986" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.280652057968066" CI_START="6.3193479420319285" DF="0.0" EFFECT_SIZE="10.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" NO="2" P_CHI2="1.0" P_Z="3.948214557216494E-7" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="5.071437731000124">
<NAME>Attention</NAME>
<CONT_DATA CI_END="14.280652057968066" CI_START="6.3193479420319285" EFFECT_SIZE="10.299999999999997" ESTIMABLE="YES" MEAN_1="-37.6" MEAN_2="-47.9" ORDER="93632" SD_1="7.9" SD_2="11.1" SE="2.030982247310126" STUDY_ID="STD-Panijel-1986" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Effect on carer</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93633" O_E="0.0" SE="0.0" STUDY_ID="STD-Panijel-1986" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93634" O_E="0.0" SE="0.0" STUDY_ID="STD-Panijel-1986" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Lecithin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lecithin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93635" O_E="0.0" SE="0.0" STUDY_ID="STD-Panijel-1986" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.12" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Reported conclusions</NAME>
<TR>
<TH>
<P>Reported conclusion</P>
</TH>
<TH>
<P>Source</P>
</TH>
</TR>
<OTHER_DATA ORDER="1150" STUDY_ID="STD-Panijel-1986">
<TR>
<TD>
<P>"a highly significant superiority of the lecithin-preparation compared with the placebo (p&lt;0.0001) was shown"</P>
</TD>
<TD>
<P>English abstract</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>